29
Participants
Start Date
September 27, 2024
Primary Completion Date
January 31, 2026
Study Completion Date
January 31, 2026
MB310
Live bacterial therapeutic for oral administration
Placebo
MB310-matching placebo for oral administration
Vancomycin
Antibiotic
Medizinische Universitaet Innsbruck, Innsbruck
Klinikum Klagenfurt am Woerthersee, Klagenfurt
Uniklinikum Salzburg, Salzburg
Medizinische Universitaet Wien, Vienna
Acibadem City Clinic, Tokuda Hospital, Sofia
Diagnostic Consulting Center Convex EOOD, Sofia
Medical Center Rusemed EOOD, Sofia
University Multiprofile Hospital for Active Treatment, Stara Zagora
Diagnostic-Consulting Center, Varna
Centrum Medyczne Kermed, Bydgoszcz
Korczowski Bartosz, Gabinet Lekarski, Rzeszów
Panstwowy Instytut Medyczny MSWiA - Klinika Gastroenterologi i Chorob Wewnetrznych, Warsaw
Warsaw IBD Point, Warsaw
Wojskowy Instytut Medyczny - Panstwowy Instytut Badawczy, Klinika Gastroenterologii i Chorob Wewnetrznych, Warsaw
University Hospital Birmingham, Birmingham
Addenbrooke's Hospital, Cambridge
St George's Hospital, London
Royal Victoria Infirmary, Newcastle
Lead Sponsor
Microbiotica Ltd
INDUSTRY